News NICE will only fund Opdivo in PD-L1 lung cancer patients Pharma must apply for Cancer Drugs Funding in restricted population - NICE
News Some good news for BMS with Opdivo + natural killer cell com... But BMS dumps combination with Yervoy.
News Scotland's Opdivo decision sparks funding row Patients in Scotland will receive lung cancer drug, those in England will not.
News AZ pays Heptares $10m as cancer trial begins Phase 1 study of immuno-oncology drug candidate begins.
R&D BMS looks for cancer combos with Cormorant buy Bristol searching for new immuno-oncology combinations.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.